Saeed Sohrabpour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saeed Sohrabpour has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Reza Erfanian
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Afsaneh Mehri
Faculty of Pharmacy, Tehran Medical Sciences Islamic Azad University Tehran Iran
1 shared publication - Afshar Etemadi-Aleagha
Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Ali Bagheri Hagh
New Hearing Technologies Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
1 shared publication - Alireza Moradi
Department of Otolaryngology, SINA Clinic, Obertshausen, Germany
1 shared publication - Alireza Sharifi
Department of Otolaryngology-Head and Neck Surgery, Amir A’lam Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 31 October 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
Risk thresholds for selective neck management in cN0 lower lip SCC: a decision-analytic prediction model
Management of the clinically node-negative (cN0) neck in lower lip squamous cell carcinoma (LLSCC) remains controversial because the risk of occult metastasis must be balanced against the morbidity of elective neck dissection (END). We aimed to identify predictors of early cervical nodal failure under an observation-first strategy and to translate them into a threshold-based decision-support framework. In this multicenter retrospective cohort, 208 consecutive LLSCC patients were screened, and 74 cN0 patients treated with primary tumor resection without upfront END were included. The primary endpoint was early cervical nodal failure within 12 months, defined as failure of surveillance. A full postoperative multivariable model including DOI, tumor size, and closest histopathologic margin was fitted for individualized postoperative risk estimation. A simplified DOI-size risk stratification scheme was constructed for clinically intuitive group-level interpretation and threshold-based decision support. Discrimination, calibration with bootstrap validation and shrinkage, ROC-derived thresholds, and decision curve analysis were performed. The simplified DOI-size strata were interpreted against a prespecified 20% elective-treatment threshold, with sensitivity analyses at 15% and 25%. Early nodal failure occurred in 15 of 74 patients (20.3%). DOI (OR 1.95 per mm, 95% CI 1.19 to 3.21, P = .008) and tumor size (OR 3.06 per cm, 95% CI 1.30 to 7.18, P = .010) independently predicted failure, whereas closest histopathologic margin showed an inverse but non-significant association (OR 0.74 per mm, 95% CI 0.52 to 1.06, P = .102). The full DOI-size-margin model achieved an apparent AUC of 0.85 with acceptable calibration after optimism correction, with a shrinkage slope of 0.86 and calibration-in-the-large of 0.03. ROC-derived thresholds were DOI ≥ 7 mm and tumor size ≥ 3 cm, while DOI ≥ 6 mm was retained as a conservative clinical boundary for simplified bedside stratification. The simplified DOI-size stratification separated 12-month nodal failure risk into 0.0% in the low-risk group (0/12), 12.2% in the intermediate-risk group (5/41), and 47.6% in the high-risk group (10/21). Only the high-risk group exceeded the prespecified 20% decision boundary. Decision curve analysis demonstrated superior net benefit of the full postoperative model compared with the reduced DOI-size model and treat-all or treat-none strategies across clinically relevant thresholds. In cN0 LLSCC managed without upfront END, a full postoperative prediction model incorporating DOI, tumor size, and closest histopathologic margin provides individualized estimation of early surveillance failure risk. DOI and tumor size remain the dominant clinically interpretable variables for simplified bedside risk stratification, while closest histopathologic margin contributes postoperative risk refinement in the full model. When embedded within a threshold-based framework, this combined approach supports selective rather than routine elective neck management. External validation is warranted.
- 31 October 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
Risk thresholds for selective neck management in cN0 lower lip SCC: a decision-analytic prediction model
Management of the clinically node-negative (cN0) neck in lower lip squamous cell carcinoma (LLSCC) remains controversial because the risk of occult metastasis must be balanced against the morbidity of elective neck dissection (END). We aimed to identify predictors of early cervical nodal failure under an observation-first strategy and to translate them into a threshold-based decision-support framework. In this multicenter retrospective cohort, 208 consecutive LLSCC patients were screened, and 74 cN0 patients treated with primary tumor resection without upfront END were included. The primary endpoint was early cervical nodal failure within 12 months, defined as failure of surveillance. A full postoperative multivariable model including DOI, tumor size, and closest histopathologic margin was fitted for individualized postoperative risk estimation. A simplified DOI-size risk stratification scheme was constructed for clinically intuitive group-level interpretation and threshold-based decision support. Discrimination, calibration with bootstrap validation and shrinkage, ROC-derived thresholds, and decision curve analysis were performed. The simplified DOI-size strata were interpreted against a prespecified 20% elective-treatment threshold, with sensitivity analyses at 15% and 25%. Early nodal failure occurred in 15 of 74 patients (20.3%). DOI (OR 1.95 per mm, 95% CI 1.19 to 3.21, P = .008) and tumor size (OR 3.06 per cm, 95% CI 1.30 to 7.18, P = .010) independently predicted failure, whereas closest histopathologic margin showed an inverse but non-significant association (OR 0.74 per mm, 95% CI 0.52 to 1.06, P = .102). The full DOI-size-margin model achieved an apparent AUC of 0.85 with acceptable calibration after optimism correction, with a shrinkage slope of 0.86 and calibration-in-the-large of 0.03. ROC-derived thresholds were DOI ≥ 7 mm and tumor size ≥ 3 cm, while DOI ≥ 6 mm was retained as a conservative clinical boundary for simplified bedside stratification. The simplified DOI-size stratification separated 12-month nodal failure risk into 0.0% in the low-risk group (0/12), 12.2% in the intermediate-risk group (5/41), and 47.6% in the high-risk group (10/21). Only the high-risk group exceeded the prespecified 20% decision boundary. Decision curve analysis demonstrated superior net benefit of the full postoperative model compared with the reduced DOI-size model and treat-all or treat-none strategies across clinically relevant thresholds. In cN0 LLSCC managed without upfront END, a full postoperative prediction model incorporating DOI, tumor size, and closest histopathologic margin provides individualized estimation of early surveillance failure risk. DOI and tumor size remain the dominant clinically interpretable variables for simplified bedside risk stratification, while closest histopathologic margin contributes postoperative risk refinement in the full model. When embedded within a threshold-based framework, this combined approach supports selective rather than routine elective neck management. External validation is warranted.
- 22 June 2023
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 280 (10) , 4677-4685
Uvulopalatopharyngoplasty with and without modified thyrohyoid suspension for obstructive sleep apnea treatment: a randomized clinical trial
Purpose This study aims to compare the efficacy of Uvulopalatopharyngoplasty + Tongue Base Radiofrequency (TB-RF) and Uvulopalatopharyngoplasty + modified thyrohyoid suspension techniques + TB-RF which aimed to suspend base of tongue muscles anteriorly toward thyroid cartilage. Methods This randomized controlled trial study was conducted on 48 cases of confirmed OSA between Jan, 2019 and Aug, 2022. We divided patients into two groups. One group underwent Uvulopalatopharyngoplasty + modified thyrohyoid suspension + TB-RF technique, and another one underwent Uvulopalatopharyngoplasty + TB-RF. Then, Apnea–Hypopnea Index (AHI), mean and lowest O2 saturation, Drug-Induced Sleep Endoscopy (DISE), Epworth Sleepiness Scale (ESS), Digit Symbol Substitution Test (DSST), Stanford Subjective Snoring Scale (SSSS), and T90 indexes were evaluated before and after each surgery. Results The mean ± SD age was 39.4 ± 11.17 years. Of the 48 patients, 79.1% (n = 33) were male and 20.9% (n = 15) were female. AHI and SSSS in the Uvulopalatopharyngoplasty + modified thyrohyoid suspension group were significantly better than Uvulopalatopharyngoplasty group (P-value; 0.010). Though, there was no significant difference in terms of mean saturation, lowest desaturation, ESS, DSST, and T90 scores. The success rate in the Uvulopalatopharyngoplasty + modified thyrohyoid suspension and Uvulopalatopharyngoplasty groups, according to the Sher criteria: a minimum of 50% reduction with a final AHI less than 20, were 75% (18/24) and 41.7% (10/24), respectively. It was significantly higher in the Uvulopalatopharyngoplasty + modified thyrohyoid suspension group (P-value: 0.021). Conclusion The addition of modified thyrohyoid suspension technique to Uvulopalatopharyngoplasty have better surgical outcomes and more success rate than Uvulopalatopharyngoplasty in OSA patients. Trial registration: IRCT: IRCT20190602043791N2. https://en.irct.ir/trial/53365.
- 22 June 2023
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 280 (10) , 4677-4685
Uvulopalatopharyngoplasty with and without modified thyrohyoid suspension for obstructive sleep apnea treatment: a randomized clinical trial
Purpose This study aims to compare the efficacy of Uvulopalatopharyngoplasty + Tongue Base Radiofrequency (TB-RF) and Uvulopalatopharyngoplasty + modified thyrohyoid suspension techniques + TB-RF which aimed to suspend base of tongue muscles anteriorly toward thyroid cartilage. Methods This randomized controlled trial study was conducted on 48 cases of confirmed OSA between Jan, 2019 and Aug, 2022. We divided patients into two groups. One group underwent Uvulopalatopharyngoplasty + modified thyrohyoid suspension + TB-RF technique, and another one underwent Uvulopalatopharyngoplasty + TB-RF. Then, Apnea–Hypopnea Index (AHI), mean and lowest O2 saturation, Drug-Induced Sleep Endoscopy (DISE), Epworth Sleepiness Scale (ESS), Digit Symbol Substitution Test (DSST), Stanford Subjective Snoring Scale (SSSS), and T90 indexes were evaluated before and after each surgery. Results The mean ± SD age was 39.4 ± 11.17 years. Of the 48 patients, 79.1% (n = 33) were male and 20.9% (n = 15) were female. AHI and SSSS in the Uvulopalatopharyngoplasty + modified thyrohyoid suspension group were significantly better than Uvulopalatopharyngoplasty group (P-value; 0.010). Though, there was no significant difference in terms of mean saturation, lowest desaturation, ESS, DSST, and T90 scores. The success rate in the Uvulopalatopharyngoplasty + modified thyrohyoid suspension and Uvulopalatopharyngoplasty groups, according to the Sher criteria: a minimum of 50% reduction with a final AHI less than 20, were 75% (18/24) and 41.7% (10/24), respectively. It was significantly higher in the Uvulopalatopharyngoplasty + modified thyrohyoid suspension group (P-value: 0.021). Conclusion The addition of modified thyrohyoid suspension technique to Uvulopalatopharyngoplasty have better surgical outcomes and more success rate than Uvulopalatopharyngoplasty in OSA patients. Trial registration: IRCT: IRCT20190602043791N2. https://en.irct.ir/trial/53365.
- 5 December 2022
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (2) , 151-157
Therapeutic effects of Rosa canina, Urtica dioica and Tanacetum vulgare herbal combination in treatment of tinnitus symptoms: A double‐blind randomised clinical trial
Objective: To evaluate the effect of Neurotec® herbal capsule (100 mg twice a day for 3 months) on the tinnitus symptoms in comparison with the placebo.Design: A double‐blind randomised clinical trial.Setting: Otolaryngology clinic of Baqiyatallah Hospital.Participants: Patients suffering from subjective tinnitus.Main Outcome Measures: Pure tone audiometry was measured at .5, 1, 2, 4 and 6 kHz frequencies before and after the third month of intervention. In addition, Tinnitus Handicap Inventory (THI) questionnaire as well as visual analogue scale (VAS) for tinnitus loudness, daily annoyance, daily life or sleep disturbance, daily perception and mood alteration were evaluated.Results: Finally, 103 (69 males and 34 females) patients with a mean age of 51.33 ± 13.91 years were analysed. In contrast with control group, patients in intervention group showed a remarkable decrease in THI score after 3 months of treatment (p < .05). Although both groups had improvements in VAS scores, mood disturbance, daily tinnitus perception and daily life alteration scores were only improved in the intervention group. The mean pure tone air and bone conduction were not significantly different between the control and the intervention group at baseline and 3 months after the intervention at .5, 1, 2 and 4 kHz (p > .05).Conclusion: A 3‐month treatment with Neurotec capsules in addition to patient education is of benefit for managing symptoms in patients with chronic tinnitus.
- 5 December 2022
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (2) , 151-157
Therapeutic effects of Rosa canina, Urtica dioica and Tanacetum vulgare herbal combination in treatment of tinnitus symptoms: A double‐blind randomised clinical trial
Objective: To evaluate the effect of Neurotec® herbal capsule (100 mg twice a day for 3 months) on the tinnitus symptoms in comparison with the placebo.Design: A double‐blind randomised clinical trial.Setting: Otolaryngology clinic of Baqiyatallah Hospital.Participants: Patients suffering from subjective tinnitus.Main Outcome Measures: Pure tone audiometry was measured at .5, 1, 2, 4 and 6 kHz frequencies before and after the third month of intervention. In addition, Tinnitus Handicap Inventory (THI) questionnaire as well as visual analogue scale (VAS) for tinnitus loudness, daily annoyance, daily life or sleep disturbance, daily perception and mood alteration were evaluated.Results: Finally, 103 (69 males and 34 females) patients with a mean age of 51.33 ± 13.91 years were analysed. In contrast with control group, patients in intervention group showed a remarkable decrease in THI score after 3 months of treatment (p < .05). Although both groups had improvements in VAS scores, mood disturbance, daily tinnitus perception and daily life alteration scores were only improved in the intervention group. The mean pure tone air and bone conduction were not significantly different between the control and the intervention group at baseline and 3 months after the intervention at .5, 1, 2 and 4 kHz (p > .05).Conclusion: A 3‐month treatment with Neurotec capsules in addition to patient education is of benefit for managing symptoms in patients with chronic tinnitus.
- Open Access
- 11 April 2021
- Published by Knowledge E DMCC in Case Reports in Clinical Practice
A Malignant Solitary Fibrous Tumor of the Parotid Gland: A Case Report
A Solitary Fibrous Tumor (SFT) is a soft tissue tumor that appears exceedingly rare in the parotid gland. The literature review suggested that approximately 12%-22% of these cases behave aggressively. Besides, only 4 cases of histological malignant parotid gland SFT are reported in the English literature. We presented a 65-year-old cigarette-smoker man with a fix and tender mass over the left parotid and submandibular areas. On physical examination, the marginal branch of the facial nerve was paralyzed. The left total parotidectomy and neck dissection levels 1 and 2 were performed with preoperative embolization procedure and adjuvant radiotherapy for the patient. The results of the follow-up examination were unremarkable after 11 months. In this case report, we aimed to increase awareness on SFTs, although rare, among clinicians and pathologists. Accordingly, it should be considered in the differential diagnosis of soft-tissue tumors in the major salivary glands for better management.
- 11 April 2021
- Published by Knowledge E DMCC in Case Reports in Clinical Practice
Open AccessA Malignant Solitary Fibrous Tumor of the Parotid Gland: A Case Report
A Solitary Fibrous Tumor (SFT) is a soft tissue tumor that appears exceedingly rare in the parotid gland. The literature review suggested that approximately 12%-22% of these cases behave aggressively. Besides, only 4 cases of histological malignant parotid gland SFT are reported in the English literature. We presented a 65-year-old cigarette-smoker man with a fix and tender mass over the left parotid and submandibular areas. On physical examination, the marginal branch of the facial nerve was paralyzed. The left total parotidectomy and neck dissection levels 1 and 2 were performed with preoperative embolization procedure and adjuvant radiotherapy for the patient. The results of the follow-up examination were unremarkable after 11 months. In this case report, we aimed to increase awareness on SFTs, although rare, among clinicians and pathologists. Accordingly, it should be considered in the differential diagnosis of soft-tissue tumors in the major salivary glands for better management.